DA
VRDN icon

DCF Advisers’s Viridian Therapeutics VRDN Stock Holding History

DCF Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$629K Sell
32,150
-20,550
-39% -$610K 0.17% 70
2025
Q4 		$1.64M Sell
52,700
-9,329
-15% -$256K 0.44% 55
2025
Q3 		$1.34M Hold
62,029
– – 0.43% 57
2025
Q2 		$867K Hold
62,029
– – 0.4% 57
2025
Q1 		$836K Buy
62,029
+32,279
+109% +$550K 0.4% 60
2024
Q4 		$570K Buy
29,750
+15,250
+105% +$332K 0.28% 67
2024
Q3 		$330K Sell
14,500
-3,250
-18% -$53.1K 0.13% 80
2024
Q2 		$231K Buy
17,750
+3,250
+22% +$45K 0.12% 84
2024
Q1 		$254K Buy
14,500
+5,000
+53% +$96.9K 0.13% 72
2023
Q4 		$207K Sell
9,500
-4,000
-30% -$63.1K 0.11% 72
2023
Q3 		$207K Sell
13,500
-5,500
-29% -$105K 0.11% 83
2023
Q2 		$452K Buy
+19,000
New +$487K 0.24% 64

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return